Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling
Cells · 2026
DOI: 10.3390/cells15161436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Waleed Khaled Younis Albahadly und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq. Hauptthemen laut MEDLINE: Cisplatin, NAD(P)H Dehydrogenase (Quinone), Niacinamide, Antioxidants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cisplatin is a widely used chemotherapeutic agent whose clinical application is often limited by severe hepatorenal toxicity associated with oxidative stress and cellular injury. Nicotinamide riboside (NR), a natural precursor of nicotinamide adenine dinucleotide (NAD+), has emerged as a promising cytoprotective compound with antioxidant and metabolic regulatory properties. This study investigated the protective effects of NR against cisplatin-induced hepatorenal toxicity and explored its potential mechanisms of action.
Methods
Thirty-six adult male Wistar rats were randomly assigned to four groups (n = 6): control, cisplatin (7 mg/kg, i.p.), nicotinamide riboside (50 mg/kg/day, orally), and cisplatin plus NR. Renal and hepatic function biomarkers, lipid profile parameters, oxidative stress markers, and antioxidant status were evaluated. Relative mRNA expression of Nrf2 and NQO1 was determined using RT-qPCR. Histopathological examinations of liver and kidney tissues were also performed.
Results
Cisplatin administration induced marked hepatorenal injury, evidenced by significant elevations in serum KIM-1 (395.27 vs. 116.04 ng/mL), urea (71.16 vs. 21.33 mg/dL), creatinine (3.49 vs. 0.26 mg/dL), AST (325.83 vs. 95.16 U/L), and ALT (102.83 vs. 45.50 U/L), accompanied by dyslipidemia, oxidative stress, and severe histopathological alterations. NR treatment significantly attenuated these changes, reducing KIM-1, urea, creatinine, AST, and ALT by 55.5%, 47.8%, 48.1%, 55.4%, and 33.5%, respectively, compared with the cisplatin group. NR also improved antioxidant status by increasing GSH and SOD levels while reducing MDA and NO concentrations. Hepatic NAD+ levels and the NAD+/NADH ratio were significantly decreased by cisplatin and significantly restored by NR treatment. In addition, NR significantly upregulated the relative mRNA expression of Nrf2 and NQO1 and markedly preserved hepatic and renal histological architecture. Pharmacological inhibition of Nrf2 with ML385 significantly attenuated these protective effects of NR across biochemical, lipid, and oxidative stress parameters, confirming that they are, at least in part, Nrf2-dependent.
Conclusions
Nicotinamide riboside exerts protective effects against cisplatin-induced hepatorenal toxicity that are mechanistically linked to activation of the Nrf2/NQO1 antioxidant pathway and restoration of hepatic NAD+ homeostasis. This finding supports the potential of NR as an adjunctive strategy for mitigating cisplatin-associated hepatorenal injury and warrants further preclinical and clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq.
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Al-Ameed, Karbala 56001, Iraq.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Kufa, Najaf 54001, Iraq.
- Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ahl Al Bayt University Kerbala, Karbala 56001, Iraq.
ORCID-Profile: Mohammed Ibrahim Rasool, Haider Falih Shamikh Al-Saedi, Samer Ali Hasan, Mohammed Abdulaali Sahib
Zitieren
APA
Albahadly, W. K. Y., Rasool, M. I., Al-Saedi, H. F. S., Al-Kareem, Z. A., Hasan, S. A., Sahib, M. A., & ALtrufi, M. H. (2026). Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling. Cells. https://doi.org/10.3390/cells15161436
Vancouver
Albahadly WKY, Rasool MI, Al-Saedi HFS, Al-Kareem ZA, Hasan SA, Sahib MA, et al. Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling. Cells. 2026. doi:10.3390/cells15161436
BibTeX
@article{Albahadly2026,
author = {Albahadly, Waleed Khaled Younis and Rasool, Mohammed Ibrahim and Al-Saedi, Haider Falih Shamikh and Al-Kareem, Zahraa Abed and Hasan, Samer Ali and Sahib, Mohammed Abdulaali and ALtrufi, Meeqaat H},
title = {Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15161436}
}
EUVIMED